|
Match
|
Document |
Document Title |
|
|
7078045 |
Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
A pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis, which comprises 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and...
|
|
|
7074429 |
Fosinopril sodium tablet formulation
Stable tablets comprising fosinopril sodium are prepared by employing either stearic acid or zinc stearate as the lubricant.
|
|
|
7074417 |
Multiple-delayed release anti-viral product, use and formulation thereof
An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the C max for the anti-viral product being reached in less...
|
|
|
7074428 |
Quick disintegrating tablet in buccal cavity and manufacturing method thereof
The present invention pertains to a quick disintegrating tablet in buccal cavity, characterized in that drug-containing particles with a mean particle diameter of approximately 50 to approximately...
|
|
|
7070804 |
Chewable tablet containing lysine
A tablet with enhanced compliance by humans, in particular children and/or juveniles, comprising:
(a) a vitamin; (b) lysine or a pharmaceutically acceptable salt thereof; (c) a sweetener;...
|
|
|
7070817 |
Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases
The invention relates to an herbal composition comprising extract of plant Moringa Oleifera , a member of family Moringaceae, plant Piper Nigrum , a member of family Piperaceae and plant ...
|
|
|
7071228 |
Method of treating musculoskeletal and connective tissue inflammations
A method of treating said musculoskeletal and connective tissue inflammations including osteoarthritis and associated articular and periarticular inflammations, and non-articular Rheumatism...
|
|
|
7071202 |
Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6...
|
|
|
7070811 |
Directly compressible formulations of azithromycin
The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable...
|
|
|
7067149 |
Fast disintegrating tablet
The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterized in that it is based on...
|
|
|
RE39149 |
Method of administering azithromycin
An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets;...
|
|
|
7067148 |
Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
A pharmaceutical composition with β-sheet microcrystalline cellulose with improved potency life and methods of preparation therefor. Improved thyroid hormone pharmaceutical compositions comprising...
|
|
|
7067154 |
Pharmaceutical compositions containing Vitamin D and calcium, their preparation and therapeutic use
Described herein is a pharmaceutical composition containing Vitamin D and calcium, comprising a binding agent chosen from among the group consisting of: propylene glycol, a polyethylene glycol...
|
|
|
7063857 |
Use of macrolide compounds for the treatment of dry eye
The present invention provides an agent for treating a dry eye, which contains a macrolide compound such as FK506.
|
|
|
7063861 |
Bioavailable composition of natural and synthetic HCA
The invention relates to a composition comprising hydroxycitric acid (HCA) in combination with either one or both of garcinol and anthocyanin, and its use as a weight-loss therapy in animal...
|
|
|
7060294 |
Compressed tablet formulation
This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the...
|
|
|
7060295 |
Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the...
|
|
|
7056495 |
Solid dose delivery vehicle and methods of making same
The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and...
|
|
|
7056534 |
Coated potassium chloride granules and tablets
This invention provides extended release potassium chloride granules consisting essentially of potassium chloride crystals having a mesh size of about 20–60 mesh that are coated only with...
|
|
|
7056531 |
Sustained release compositions for orally administered substances and methods
Sustained release composition for orally administered active substances that comprises maltodextrin and cellulose. This composition is suitable for forming tablets, gels when exposed to the fluids...
|
|
|
7056539 |
Process and product extracted from herbal composition useful in controlling diabetes mellitus type II
An active substance is extracted from an herbal composition which comprises: Centaurii umbellatum, Gentianaceae (centaury plant), Teraxacum officinale, Asteraceae (dandelion root), Juniperi...
|
|
|
7052717 |
Storage stable thyroxine active drug formulations and methods for their production
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance and an...
|
|
|
7048945 |
Timed pulsatile drug delivery systems
A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a...
|
|
|
7049322 |
Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an...
|
|
|
7045147 |
Controlled release peroral compositions of levosimendan
The invention relates to peroral pharmaceutical compositions which release levosimendan in a controlled fashion with reduced occurrence of undesired effects. Levosimendan, or...
|
|
|
7045155 |
Dietary supplements comprising soy hypocotyls containing at least one isoflavone
Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules...
|
|
|
7045140 |
Therapeutic delivery of carbon monoxide
Metal carbonyls are used to deliver CO having biological activity, for example vasodilatation and inhibition of transplant rejection. The metal of the carbonyl is typically of groups 7 to 10, e.g....
|
|
|
7041303 |
Use of moxonidine for postmyocardial infarction treatment
A method of treating myocardial damage secondary to myocardial infarction using moxonidine or a physiologically compatible salt thereof. Pharmaceutical preparations containing moxonidine and its...
|
|
|
7041244 |
Method for producing moulded bodies
A process for producing tablets comprising one or more active substances, in which pulverulent to granular starting components are shaped and then solidified, wherein the solidification takes place...
|
|
|
7041317 |
Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino] pyrimidine trihydrochloride as active ingredient
A sustained-release formulation of 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]e
thylamino]pyrimidine trihydrochloride coated with a release-controlling film comprising a...
|
|
|
7041316 |
Stable oral pharmaceutical dosage forms
The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such...
|
|
|
7041319 |
Fenofibrate pharmaceutical composition having high bioavailabilty
The invention provides fenofibrate tablets comprising granulates, wherein the granulates can comprise carrier particles, micronized fenofibrate, and at least one hydrophilic polymer.
|
|
|
7041314 |
GPE analogs and peptidominetics
This invention relates to analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic and...
|
|
|
7037523 |
Controlled release compositions for macrolide antimicrobial agents
The present invention provides a controlled release pharmaceutical composition of an acid labile, poorly soluble drug having pH dependent solubility profile in aqueous environment. In a preferred...
|
|
|
7037524 |
Oral delivery of a botanical
A method of producing a processed kava product involves using an extraction solvent, such as liquid CO 2 , to preferentially extract different kavalactones from the source material at different...
|
|
|
7037519 |
Nutritional supplement and methods of making
Nutritional supplements and methods for making same supplement the intake of nutrition from foods. Garlic and apple cider vinegar are currently available in separate forms and are popular with...
|
|
|
7037529 |
Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a...
|
|
|
7033582 |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
The present invention involves the administration of Copolymer 1 (glatiramer acetate) to treat inflammatory, non-autoimmune central nervous system (CNS) diseases, alleviate the symptoms thereof,...
|
|
|
7029701 |
Composition for the treatment and prevention of ischemic events
The invention relates to pharmaceutical compositions comprising omeprazole and aspirin wherein the combination is useful for the treatment and prevention of cardiovascular events including heart...
|
|
|
7029699 |
Soft chewable tablets
The present invention relates to a compressed, chewable tablet containing at least one active ingredient, a water-disintegratable, compressible carbohydrate and a binder. These components are dry...
|
|
|
7030106 |
Sterol absorption inhibitor compositions
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted...
|
|
|
7025984 |
Compositions and methods for body weight management
The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by...
|
|
|
7025989 |
Multiple-delayed released antibiotic product, use and formulation thereof
An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the C max for the antibiotic product being reached in less...
|
|
|
7022338 |
Tablets comprising micro-organisms and method for preparation of the tablets
Tablet containing living micro-organisms, produced from a pressed tablet material comprising micro-organisms and oligosaccharides and/or polysaccharides, the tablet material also comprising at...
|
|
|
7022341 |
Pharmaceutical compositions containing epinastine and pseudoephedrine
The present invention relates to novel oral pharmaceutical compositions comprising as pharmaceutically active compounds a combination of an antihistaminic-effective amount of epinastine or a...
|
|
|
7022345 |
Oral solid pharmaceutical formulations with pH-dependent multiphasic release
Oral solid pharmaceutical compositions with pH-dependent multiphasic release, containing, as active ingredient, a molecule useful in the inflammatory bowel disease therapy, are described, being...
|
|
|
7022342 |
Controlled release oral dosage form of beta-adrenergic blocking agents
A sustained release beta-adrenergic receptor blocking agent, preferably propranolol, formulation.
|
|
|
7022340 |
Pharmaceutical composition as solid dosage form and method for manufacturing thereof
The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof....
|
|
|
7018653 |
Method for preparing solid dosage form of desmopressin
The present invention relates to a novel method for the preparation of a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, comprising providing a desmopressin...
|
|
|
7018645 |
Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
A water soluble, biodegradable reverse thermal gelation system comprising a mixture of at least two types of tri-block copolymer components is disclosed. The tri-block copolymer components are made...
|